- Home
- SEVN vs THTX Comparison
SEVN vs THTX Comparison
Compare SEVN & THTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- THTX
- Stock Information
- Founded
- SEVN 1986
- THTX 1993
- Country
- SEVN United States
- THTX Canada
- Employees
- SEVN N/A
- THTX N/A
- Industry
- SEVN Real Estate Investment Trusts
- THTX Biotechnology: Pharmaceutical Preparations
- Sector
- SEVN Real Estate
- THTX Health Care
- Exchange
- SEVN Nasdaq
- THTX Nasdaq
- Market Cap
- SEVN 156.9M
- THTX 144.8M
- IPO Year
- SEVN N/A
- THTX N/A
- Fundamental
- Price
- SEVN $10.50
- THTX $3.24
- Analyst Decision
- SEVN Strong Buy
- THTX Hold
- Analyst Count
- SEVN 2
- THTX 1
- Target Price
- SEVN $13.50
- THTX N/A
- AVG Volume (30 Days)
- SEVN 78.3K
- THTX 249.2K
- Earning Date
- SEVN 07-28-2025
- THTX 10-09-2025
- Dividend Yield
- SEVN 10.67%
- THTX N/A
- EPS Growth
- SEVN N/A
- THTX N/A
- EPS
- SEVN 1.04
- THTX N/A
- Revenue
- SEVN $29,272,000.00
- THTX $84,378,000.00
- Revenue This Year
- SEVN $7.45
- THTX N/A
- Revenue Next Year
- SEVN $1.12
- THTX $13.76
- P/E Ratio
- SEVN $10.08
- THTX N/A
- Revenue Growth
- SEVN N/A
- THTX 2.19
- 52 Week Low
- SEVN $10.01
- THTX $1.12
- 52 Week High
- SEVN $14.66
- THTX $3.25
- Technical
- Relative Strength Index (RSI)
- SEVN 42.65
- THTX 74.26
- Support Level
- SEVN $10.20
- THTX $3.18
- Resistance Level
- SEVN $10.95
- THTX $3.22
- Average True Range (ATR)
- SEVN 0.24
- THTX 0.02
- MACD
- SEVN 0.08
- THTX -0.01
- Stochastic Oscillator
- SEVN 52.13
- THTX 90.00
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.